Understanding medicine identity

Begin with the active substance

The generic or nonproprietary name identifies the active substance used to discuss a medicine independently of its brand. A proprietary name identifies a commercial product. The public Luang Pharma portfolio uses generic identities and withholds proposed proprietary medicine names.

The distinction between an active ingredient and a finished drug product is explained in the FDA Drugs@FDA glossary. The substance name is one part of product identification. A complete enquiry should also preserve the form of the substance when specified, including an ester or salt designation. Omitting that information can change the subject of the enquiry.

Identify the actual presentation

Dosage form describes the physical presentation, such as a tablet, capsule, solution or powder for preparation. Strength states the amount or concentration of active substance. The pack presentation adds the container and quantity, for example the volume in a vial or number of units in a carton.

Keep these fields separate in a product brief. A container’s nominal capacity, its fill volume and the amount of active substance are not interchangeable. The intended route also matters, and should only be taken from the relevant product information rather than inferred from the shape of the container.

What a matching name does not establish

Two records may use the same generic name without establishing equivalent products. FDA generic drug facts explains the requirements attached to FDA-approved generics in the United States. Those approval-based conclusions must not be extended to an unapproved catalogue candidate or to another jurisdiction without the relevant evidence.

For a commercial or technical comparison, first check whether the active substance, strength, dosage form and presentation actually match. Then identify the authorisation holder, site and regulatory status. Similar packaging or a common ingredient does not resolve those questions.

Use the right source for the question

A scientific paper may explain a mechanism or report findings in a particular study. An approved product document addresses a particular medicine and jurisdiction. A public portfolio communicates the identity of a proposed line. Each source serves a different purpose.

When reviewing a document, record who published it, what exact product or material it describes, and when it was issued. If it refers to a different strength or presentation, retain that distinction in your notes. Do not silently replace missing product information with details copied from a nearby search result.

A practical identity checklist

• Generic name and any stated salt, ester or combination components.
• Dosage form and release characteristic, if specified.
• Strength with the full unit and denominator.
• Container, fill quantity and units per pack.
• Route, where explicitly stated in the relevant information.
• Country, authorisation holder and product approval reference where applicable.

If a field is absent or ambiguous, record the question and request clarification before comparing products or preparing a formal specification. An unresolved ambiguity is more useful than a guessed answer.

Using the Luang Pharma portfolio

The portfolio is intended for professional discussion of development interests. It is not an approved label, prescribing information or a current stock list. The initial Boten manufacturing modules are also narrower than the complete portfolio, so an entry does not establish installed production capability.

For an enquiry, quote the portfolio reference together with the generic identity and target country. Read strength, concentration and pack size for the related quantitative distinctions.

Identity and regulatory status are separate fields

A technically complete product identity still does not answer whether that product is authorised, marketed, manufactured at a particular site or eligible for import into a destination. Those are separate status questions. Keep the product identity stable while recording the jurisdiction, authorisation holder, application or registration reference and current status from the competent authority.

US FDA Orange Book entries illustrate the point: the database identifies FDA-approved drug products and, for certain multisource prescription products, FDA therapeutic-equivalence evaluations. Those conclusions belong to the listed FDA-approved products. A matching generic name in another portfolio does not inherit them.

Common comparison traps

Do not collapse salt and base names, immediate- and modified-release forms, oral and injectable presentations, or different strengths into one supposedly equivalent item. Device-specific presentations and combination products also require their own identity. A reference product can be useful context without becoming the identity of the product being reviewed.

A defensible comparison therefore records both matches and mismatches. If the dosage form, route, release characteristic or exact strength is unresolved, stop at that point and request controlled product information rather than filling the gap from a comparator.